Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aidan Fry

With over 20 years of experience of reporting on the global pharmaceutical industry, Aidan focuses in his role as editor of Generics bulletin particularly on commercial, regulatory and legal issues affecting the generic, biosimilar, value-added and OTC medicines industries. This includes in-depth analyses of corporate strategy, legislative changes, legal precedents and product perspectives. He regularly interviews leading industry executives and moderates prestigious events. Aidan also oversees the Global Generics & Biosimilars Awards. Aidan speaks fluent German and has a particular affection for maps.
Advertisement
Set Alert for Articles By Aidan Fry

Latest From Aidan Fry

Laurus Buys Way Into South African ARV Tenders

India’s Laurus Labs is aiming to supply antiretrovirals through South Africa’s public tender system after agreeing a deal to buy Aspen Pharmacare’s Phekolong Pharmaceuticals subsidiary.

Deals South Africa

US Patent Reform Would Raise Drug Costs

By weakening ways to challenge drug patent thickets, proposed legislation to reform US patent law would extend brand monopolies and increase spending on medicines, the Association for Accessible Medicines is warning.

Intellectual Property Legislation

US Study Lends Support To Polypill Proposals

Fixed-dose polypills containing commonly available generic cardiovascular agents could cut risks in low-income populations within the US, a randomized clinical trial suggests.

Cardiovascular Clinical Trials

Meitheal’s Heparin Launch Builds On Nanjing King-Friend Backing

Launching eight heparin vial presentations in the US is evidence of how injectables specialist Meitheal Pharmaceuticals intends to leverage the vertically-integrated production capacity of its Chinese parent group NKF.

Business Strategies United States

Hikma Starts Added-Value Push With Heparin Syringes

Heparin marks the start of Hikma’s pre-filled syringe portfolio in the US as the company looks to add value and differentiation to its injectables portfolio and pipeline, commercial and business development head Dan Motto told Generics Bulletin.
Business Strategies Launches

Interchangeability Is Inherent To Biosimilarity

Interchangeability should be seen as a scientific concept rather than a therapeutic choice of biosimilar or reference biologic, Spanish physicians argue in a journal article.

Biosimilars Regulation
See All
Advertisement
UsernamePublicRestriction

Register